Stock PSYG PSYENCE GROUP INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Psyence Group Inc.

Equities

PSYG

CA74449Q1063

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange
Other stock markets
 03:43:26 2024-04-22 pm EDT 		5-day change 1st Jan Change
0.03 CAD +20.00% Intraday chart for Psyence Group Inc. 0.00% -40.00%
Mar. 26 Psyence Group Closes Strategic Restructuring of Its Non-Clinical Business MT
Mar. 26 An undisclosed buyer completed the acquisition of Mind Health Ltd and Psyence Uk Group Ltd from Psyence Group Inc.. CI

Valuation

Fiscal Period: March 2021 2022 2023
Capitalization 1 29.94 8.553 16.11
Enterprise Value (EV) 1 23.9 6.387 13.78
P/E ratio -1.32 x -1.86 x -1.9 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA -6.29 x -1.43 x -2.34 x
EV / FCF - -2,179,350 x -10,056,786 x
FCF Yield - -0% -0%
Price to Book 4.65 x 3.15 x 12.1 x
Nbr of stocks (in thousands) 85,529 85,529 123,954
Reference price 2 0.3500 0.1000 0.1300
Announcement Date 6/30/21 7/5/22 7/27/23
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2021 2022 2023
Net sales - - -
EBITDA 1 -3.798 -4.461 -5.879
EBIT 1 -3.825 -4.508 -5.966
Operating Margin - - -
Earnings before Tax (EBT) 1 -13.54 -4.601 -6.082
Net income 1 -13.54 -4.601 -6.082
Net margin - - -
EPS 2 -0.2644 -0.0538 -0.0683
Free Cash Flow - -2.93 -1.37
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 6/30/21 7/5/22 7/27/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2021 2022 2023
Net Debt 1 - - -
Net Cash position 1 6.04 2.17 2.34
Leverage (Debt/EBITDA) - - -
Free Cash Flow - -2.93 -1.37
ROE (net income / shareholders' equity) - -101% -301%
ROA (Net income/ Total Assets) - -50.8% -89.2%
Assets 1 - 9.05 6.815
Book Value Per Share 2 0.0800 0.0300 0.0100
Cash Flow per Share 2 0.0700 0.0400 0.0200
Capex 1 0.43 0.16 0.26
Capex / Sales - - -
Announcement Date 6/30/21 7/5/22 7/27/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
PSYENCE GROUP INC. Stock Psyence Group Inc.
-40.00% 3.05M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. PSYG Stock
  4. Financials Psyence Group Inc.